Tirzepatide
Checked Oct 11, 2026 · 19 sources checked
Tirzepatide is a weekly injection that acts on the receptors for two gut hormones, GLP-1 and GIP, so it is called a "dual agonist". It lowers blood sugar and reduces appetite. Eli Lilly makes it. In the US it is sold by prescription as Mounjaro for type 2 diabetes and as Zepbound for long-term weight management. Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. In August 2026 Mounjaro was approved to lower the risk of heart attack, stroke and heart-related death in high-risk adults with type 2 diabetes. That approval rests on a trial against another GLP-1 drug, not placebo. Two trials have compared it directly with semaglutide. Large outcome trials in obesity are still running.
Education only, not medical advice. Talk to a clinician about your own situation.
Attention and coverage on this topic — not proof. Receipts below.
Reuters · Sep 30, 2026
STAT · Sep 30, 2026
USA Today · Aug 28, 2026
Steady, high attention. English Wikipedia's Tirzepatide article had 32,464, 37,422 and 34,205 views in July, August and September 2026. PubMed added 125 records in the 30 days to Oct 11 2026, in line with its prior rate of about 121 a month (363 in the preceding 90 days). This is sustained interest, not a spike, so we do not use a "getting hot" label.
In adults with obesity, or overweight with a weight-related condition, and no diabetes, weekly tirzepatide reduced body weight by 15.0% to 20.9% on average across the three doses tested over 72 weeks, versus 3.1% with placebo. Side effects, mostly gastrointestinal, led 4.3% to 7.1% of people on tirzepatide to stop treatment, versus 2.6% on placebo.
For adults with obesity and no diabetes, does tirzepatide reduce heart attacks, strokes, heart-failure events and deaths?
If SURMOUNT-MMO (NCT05556512) shows no reduction in its primary composite versus placebo, we would say tirzepatide's weight loss in obesity without diabetes has not been shown to cut hard cardiovascular events. A clear reduction would move this into "What we know".
Any SURMOUNT-MMO safety signal (for example in deaths from any cause) would be added to "What we know" whatever the efficacy result.
Word on the street
Who's covering it lately. Coverage means people are talking about it; it isn't evidence, and it never changes our read.
- Reuters · Sep 30, 2026Read the coverage ↗
- STAT · Sep 30, 2026Read the coverage ↗
- USA Today · Aug 28, 2026Read the coverage ↗
For the pros: claims, studies and receipts19 sources · tap to open
8 reviewed claim records · 19 linked source receipts Inspect source receipts
Maturity: source checked
In adults with obesity, or overweight with a weight-related condition, and no diabetes, weekly tirzepatide reduced body weight by 15.0% to 20.9% on average across the three doses tested over 72 weeks, versus 3.1% with placebo. Side effects, mostly gastrointestinal, led 4.3% to 7.1% of people on tirzepatide to stop treatment, versus 2.6% on placebo.
Adults with BMI ≥30, or ≥27 with a weight-related complication, without diabetes · Outcome: Percent change in body weight; discontinuation for adverse eventsConfidence applies to this claim and context.
Identity
Metabolic / obesity · active ingredient
Identity checked Oct 7, 2026. This establishes the catalog name; evidence assessment is separate.
Checked facts
- In adults with obesity, or overweight with a weight-related condition, and no diabetes, weekly tirzepatide reduced body weight by 15.0% to 20.9% on average across the three doses tested over 72 weeks, versus 3.1% with placebo. Side effects, mostly gastrointestinal, led 4.3% to 7.1% of people on tirzepatide to stop treatment, versus 2.6% on placebo. PMID 35658024 ↗
- In adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the apnea-hypopnea index by about 20 to 24 more events per hour than placebo over 52 weeks, in two trials (with and without PAP therapy). PMID 38912654 ↗
- In a head-to-head trial in adults with obesity without diabetes, tirzepatide reduced body weight more than semaglutide over 72 weeks (20.2% vs 13.7%). PMID 40353578 ↗
- In people with heart failure with preserved ejection fraction and obesity, tirzepatide lowered the combined risk of cardiovascular death or worsening heart failure versus placebo (9.9% vs 15.3%; hazard ratio 0.62) over a median of 104 weeks. The difference came from fewer worsening heart-failure events; cardiovascular deaths were too few to compare (8 on tirzepatide vs 5 on placebo). PMID 39555826 ↗
- In people with obesity and prediabetes treated for three years, fewer people on tirzepatide than on placebo were diagnosed with type 2 diabetes (1.3% vs 13.3%; hazard ratio 0.07). PMID 39536238 ↗
- In people with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was non-inferior to dulaglutide (another GLP-1 drug) for cardiovascular death, heart attack or stroke (12.2% vs 13.1%; hazard ratio 0.92). The trial did not show it was superior. It is the basis for the FDA cardiovascular approval of Mounjaro. PMID 41406444 ↗
- In type 2 diabetes, tirzepatide lowered HbA1c more than semaglutide over 40 weeks (by 0.15 to 0.45 percentage points more, depending on dose) and reduced weight more (SURPASS-2). PMID 34170647 ↗
- When people who had lost weight on tirzepatide were switched to placebo, they regained much of it. Weight changed by +14.0% on placebo versus -5.5% for those who stayed on tirzepatide, between weeks 36 and 88. PMID 38078870 ↗
Attention describes reviewed public attention, evidence shows study types, and confidence applies only to the stated claim. There is no overall score.
Claims
Would change this claim: If SURMOUNT-MMO (NCT05556512) shows no reduction in its primary composite versus placebo, we would say tirzepatide's weight loss in obesity without diabetes has not been shown to cut hard cardiovascular events. A clear reduction would move this into "What we know".
Source: Tirzepatide Once Weekly for the Treatment of Obesity. · PMID 35658024 · N Engl J Med · Abstract, Results: -15.0%, -19.5%, -20.9% vs -3.1%; AE discontinuation 4.3%, 7.1%, 6.2% vs 2.6% · Verify ↗Source: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight · NCT NCT04184622 · Eli Lilly and Company · Abstract, Results: -15.0%, -19.5%, -20.9% vs -3.1%; AE discontinuation 4.3%, 7.1%, 6.2% vs 2.6% · Verify ↗Mapped studies / experiment families
One experiment counts once, even with several registrations or publications. Counts above describe the headline claim.
No reviewed experiment families mapped yet.
Studies & active trials
Only papers and registered trials an editor reviewed for this page. Being listed is not a finding; the claims above say what they show.
What still isn't settled?
For adults with obesity and no diabetes, does tirzepatide reduce heart attacks, strokes, heart-failure events and deaths?
Its completed cardiovascular trials are a non-inferiority comparison with dulaglutide in type 2 diabetes and a heart-failure trial in people with HFpEF and obesity. No completed placebo-controlled trial has tested its effect on heart attacks, strokes and deaths in the broad population with obesity and no diabetes.
What would answer it: Results of SURMOUNT-MMO (NCT05556512), an event-driven placebo-controlled trial in about 15,000 adults with obesity and no diabetes (estimated primary completion 2027-10). Its primary composite is all-cause death, heart attack, stroke, coronary revascularization or heart-failure events.
Already settled: weight loss versus placebo over 72 weeks in adults with obesity (SURMOUNT-1); greater weight loss than semaglutide in a head-to-head trial (SURMOUNT-5).
Prioritize the next check →